Publication at First Faculty of Medicine |
2014
Abstract
Tocilizumab - a humanized monoclonal antibody against the receptor for interleukin 6 - has been, in the intravenous form, approved for the treatment of rheumatoid arthritis in many countries. New clinical trials have demonstrated efficacy of the drug in a subcutaneous formulation.
The optimal dose for European patients appears to be 162 mg SQ once weekly